Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...
Eli Lilly & Co. stock outperforms competitors on strong trading day
Shares of Eli Lilly & Co. LLY advanced 1.69% to $813.33 Tuesday, on what proved to be an all-around mixed trading session for ...
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Lightning Round: I prefer Eli Lilly over Regeneron
Parts of New York state faced up to five feet of snow over the last few days and more is coming across the Great Lakes region ...
STAT1d
Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves
Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.
Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...
Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...